Lisdexamphetamine for the treatment of methamphetamine withdrawal: Safety and feasibility

By: Liam Acheson, Krista Siefried (National Centre for Clinical Research on Emerging Drugs, UNSW, Australia), Nadine Ezard (St Vicnent's Hospital Sydney), & Rosemary Hansen (Insight: Centre for alcohol and other drug training and workforce development, Australia)

Description: There is currently no approved treatment for methamphetamine (MA) withdrawal. This video reports on the first pilot clinical trial conducted to determine the feasibility and safety of a tapering dose of a new pharmacotherapeutic option, Lisdexamfetamine, for the treatment of acute MA withdrawal. Lisdexamfetamine was found to be safe and feasible for the treatment of acute MA withdrawal.